Avecho Biotechnology Limited (ASX:AVE) is an Australian biotech company currently focused on a CBD (Cannabidiol) soft-gel capsule for insomnia. It is presently undergoing a pivotal Phase III clinical trial with the potential to be the first over-the-counter (OTC) CBD drug approved by Australia’s Therapeutic Goods Administration (TGA). On 24 June 2026, AVE announced its much-anticipated interim Phase III trial results, which is consistent with a treatment effect sufficient to continue at the originally planned sample size; this is the first insight on efficacy since the trial started in March 2024. The outcome has been the single largest binary risk event that AVE has now successfully crossed. The development is meaningful on a couple of fronts. First, it validates AVE’s approach and trial design, alleviating much scepticism as other peers have failed in similar clinical trials [also, AVE’s proprietary TPM (Tocopheryl Phosphate Mixture) may be contributing to the increased efficacy of the CBD drug]. Second, it increases the probability of further licensing discussions converting into transactions, for geographies outside of Australia. This would likely deliver upfront cash payments to AVE in the near term (this would follow the first licensing agreement signed with Sandoz in March 2025, securing the rights to AVE’s CBD drug for insomnia in Australia). While the share price responded favourably to the news yesterday (up +40%), AVE still looks like a biotech outlier from a valuation perspective at ~$80m market cap; a level too low given that Phase III could be completed successfully in the next ~12 months, and an existing licensing agreement signed with Sandoz. AVE also has near-term share price catalysts with additional licensing agreements with Big Pharma increasingly likely.